Jacob (Jack) V. Aranda, MD, PhD, FRCPC, FAAP IS A
NEONATOLOGIST- & CLINICAL & TRANSLATIONAL
PHARMACOLOGIST.

Currently, Dr. Aranda is the Director of Neonatology
and Professor of Pediatrics and Ophthalmology at
the State University of New York Downstate Health
Sciences University, Brooklyn New York City.

Dr. Aranda worked as Clinical Neonatologist in Level
3/4 Newborn Intensive Care Units, as a teacher and
Mentor to Medical and PhD Graduate Students
Pediatric Residents, Neonatal Fellows and Junior
Faculty.

His research focuses on the development of novel, effective and safe drug therapies for neonates. He discovered and developed caffeine citrate for apnea of prematurity a work that was awarded the 2022 NEONATAL LANDMARK AWARD by the American Academy of Pediatrics for its ongoing impact on neonatal care and outcomes worldwide. He also developed intravenous ibuprofen lysine for closure of the patent ductus arteriosus. Both caffeine and IV
ibuprofen are approved by the FDA and the European Medication Agency and are now standards of care worldwide.

The highly reproducible intermittent hypoxia neonatal rat model for oxygen induced retinopathy was developed in his Neonatal Pharmacology Laboratory. He was awarded $ 3.7 million dollars by the National Institutes of Health/National Institutes of Child Health and Development for his research on the molecular and clinical pharmacology of retinopathy of prematurity. The current focus of the research is the prevention of oxidative organ injury including BPD and ROP using nutritional pharmacologic agents such as omega 3 and omega 6 PUFAs and antioxidants.